Enriching for Low-Abundance Serum Proteins Using ProteoMiner™ and Protein-Level HPLC

  • Sophie Moggridge
  • Kelly M. FultonEmail author
  • Susan M. Twine
Part of the Methods in Molecular Biology book series (MIMB, volume 2024)


The mammalian immune system acts to protect the body from harmful diseases ranging from cancer to infection. Differentially expressed proteins as a result of such an immune response can shed light on the mechanism of disease or serve as biomarkers. These biomarkers can be used in a diagnostic capacity or as correlates of protection following vaccination. Protein levels in the circulatory system are considered representative of the system as a whole, making serum an ideal matrix for surveilling immune responses. However, serum proteomics using mass spectrometry is extremely challenging due to the complexity of the matrix and the dynamic range of protein concentration. This chapter will describe two orthogonal enrichment strategies that can be used sequentially or in isolation to improve the identification of low-abundance serum proteins by mass spectrometry.

Key words

Serum biomarkers Biomarker ProteoMiner™ Low-abundance protein enrichment Dynamic range compression Hexapeptide library 


  1. 1.
    Ahmed SS, Black S, Ulmer J (2012) New developments and concepts related to biomarker application to vaccines. Microb Biotechnol 5:233–240CrossRefGoogle Scholar
  2. 2.
    Wiederin J, Ciborowski P (2016) Immunoaffinity depletion of highly abundant proteins for proteomic sample preparation. In: Ciborowski P, Silberring J (eds) Proteomic profiling and analytical chemistry, 2nd edn. Elsevier, Boston, pp 101–114CrossRefGoogle Scholar
  3. 3.
    Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867CrossRefGoogle Scholar
  4. 4.
    Tirumalai RS, Chan KC, Prieto DA et al (2003) Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2:1096–1103CrossRefGoogle Scholar
  5. 5.
    Boschetti E, Righetti PG (2013) Low-abundance proteome discovery: state of the art and protocols. Newnes, OxfordGoogle Scholar
  6. 6.
    Di Girolamo F, Boschetti E, Chung MCM et al (2011) “Proteomineering” or not? The debate on biomarker discovery in sera continues. J Proteome 74:589–594CrossRefGoogle Scholar
  7. 7.
    Yocum AK, Yu K, Oe T, Blair IA (2005) Effect of immunoaffinity depletion of human serum during proteomic investigations. J Proteome Res 4:1722–1731CrossRefGoogle Scholar
  8. 8.
    Boschetti E, Righetti PG (2008) The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J Proteome 71:255–264CrossRefGoogle Scholar
  9. 9.
    Li L (2015) Dynamic range compression with ProteoMiner™: principles and examples. In: Posch A (ed) Proteomic profiling: methods and protocols. Springer, New York, NY, pp 99–107CrossRefGoogle Scholar
  10. 10.
    Murphy S, Dowling P (2018) DIGE analysis of ProteoMiner™ fractionated serum/plasma samples. Methods Mol Biol 1664:109–114CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Sophie Moggridge
    • 1
  • Kelly M. Fulton
    • 1
    Email author
  • Susan M. Twine
    • 1
  1. 1.Human Health Therapeutics Research CentreNational Research Council of CanadaOttawaCanada

Personalised recommendations